Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): An Integra Connect Database (ICD) retrospective observational study
Would you like to speak with a Thermo Fisher Scientific representative? Click the button below to request contact.
For Research Use only. Not for use in diagnostic procedures.